Betriu C, Redondo M, Boloix A, Gómez M, Culebras E, Picazo J J
Department of Clinical Microbiology, Hospital Clínico San Carlos, Plaza Cristo Rey s/n, 28040 Madrid, Spain.
J Antimicrob Chemother. 2001 Dec;48(6):911-3. doi: 10.1093/jac/48.6.911.
The activity of linezolid was determined against 225 recently isolated methicillin-resistant Staphylococcus aureus (MRSA) and 20 methicillin-resistant coagulase-negative staphylococci (CoNS) with decreased levels of susceptibility to teicoplanin. Linezolid activity was compared with other new agents (quinupristin-dalfopristin, trovafloxacin, moxifloxacin, levofloxacin and telithromycin) and six other antimicrobials (erythromycin, clindamycin, gentamicin, vancomycin, teicoplanin and rifampicin). The in vitro activity of linezolid was similar to that of vancomycin. Linezolid inhibited all MRSA strains at between 0.1 and 2 mg/L and all CoNS strains tested at between 0.2 and 0.5 mg/L. These results suggest that linezolid would be useful for the treatment of infections involving these organisms.
测定了利奈唑胺对225株近期分离的耐甲氧西林金黄色葡萄球菌(MRSA)和20株对替考拉宁敏感性降低的耐甲氧西林凝固酶阴性葡萄球菌(CoNS)的活性。将利奈唑胺的活性与其他新型药物(奎奴普丁-达福普汀、曲伐沙星、莫西沙星、左氧氟沙星和泰利霉素)以及其他六种抗菌药物(红霉素、克林霉素、庆大霉素、万古霉素、替考拉宁和利福平)进行了比较。利奈唑胺的体外活性与万古霉素相似。利奈唑胺在0.1至2mg/L之间抑制所有MRSA菌株,在0.2至0.5mg/L之间抑制所有测试的CoNS菌株。这些结果表明利奈唑胺可用于治疗涉及这些微生物的感染。